Regenerative Approach for Arthritis
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced mesenchymal regenerative medicine application for rheumatoid arthritis and osteoarthritis. Reduce joint inflammation, relieve chronic pain, and restore mobility naturally at our Istanbul clinic.
Can stem cell therapy help arthritis?
Mesenchymal stem cell therapy is not an approved treatment for osteoarthritis or inflammatory arthritis. Intra-articular MSC administration has been studied in knee osteoarthritis with variable pain and function results; effect sizes are modest and not consistently better than saline injection in controlled trials. Standard care — weight management, physiotherapy, analgesia, joint injections and, when indicated, joint replacement — remains the evidence-based path.
Key facts
- Approval status
- Not approved for arthritis
- OA evidence
- Modest, inconsistent effect sizes in controlled trials
- Standard care
- PT, weight management, analgesia, surgery when indicated
What we know
- Intra-articular MSC injection for knee OA has been evaluated in multiple randomised trials with mixed pain-relief signals.
What remains uncertain
- Whether MSC injection outperforms saline or hyaluronic acid in symptomatic OA over 12–24 months.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Arthritis (degenerative and inflammatory)
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Randomised evidence exists for osteoarthritis; for inflammatory arthritis it is early phase
- Main outcomes studied
- Pain
- Joint function
- Inflammatory markers
- Adverse events
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Supportive consideration alongside standard care
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Arthritis (degenerative and inflammatory) — PubMed
- Randomised controlled trials — Arthritis (degenerative and inflammatory) — PubMed
- Registered MSC trials — Arthritis (degenerative and inflammatory) — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What Is Regenerative Approach for Arthritis?
Arthritis is a group of conditions characterized by inflammation and degeneration of the joints, leading to pain, stiffness, and reduced mobility. The two most common forms — rheumatoid arthritis (RA) and osteoarthritis (OA) — affect millions of people worldwide and can significantly impact quality of life.
Traditional treatments for arthritis typically focus on managing symptoms through medications, physical therapy, and in severe cases, joint replacement surgery. However, these approaches often fail to address the underlying cause of joint deterioration and may come with significant side effects over time.
Regenerative medicine approach offers a groundbreaking regenerative approach to arthritis treatment. Mesenchymal stem cells (MSCs) derived from umbilical cord tissue possess powerful anti-inflammatory and immunomodulatory properties that can reduce joint inflammation, promote cartilage regeneration, and slow disease progression.
At StemCell Longevita in Istanbul, our specialized arthritis treatment protocol uses GMP-certified umbilical cord-derived MSCs to target the root causes of joint disease. Our medical team creates personalized care plans designed to restore joint function and improve your quality of life.
Ideal Candidates
- Patients with rheumatoid arthritis not responding to conventional DMARDs
- Individuals with moderate to severe osteoarthritis
- People experiencing chronic joint pain and stiffness
- Patients seeking alternatives to joint replacement surgery
- Those with multiple joint involvement
- Individuals with early-stage arthritis seeking to slow progression
- Patients with limited mobility due to joint inflammation
Types of Arthritis We Treat
Our regenerative medicine approach protocols are tailored to address the specific mechanisms of different arthritis types, providing targeted relief and regeneration.
Rheumatoid Arthritis
An autoimmune condition where the immune system mistakenly attacks the synovial lining of joints, causing chronic inflammation, pain, and progressive joint destruction.
Common Symptoms
- Joint swelling and warmth
- Morning stiffness lasting hours
- Symmetrical joint involvement
- Fatigue and systemic inflammation
- Joint deformity over time
- Reduced grip strength
Osteoarthritis
A degenerative joint disease characterized by the gradual breakdown of cartilage, leading to bone-on-bone friction, pain, and loss of joint flexibility.
Common Symptoms
- Joint pain during activity
- Stiffness after rest periods
- Bone spurs and joint enlargement
- Reduced range of motion
- Grinding or crackling sounds
- Weight-bearing joint pain
Benefits of Regenerative Approach for Arthritis
Immune System Modulation
MSCs regulate the overactive immune response in rheumatoid arthritis, reducing the autoimmune attack on joint tissues and decreasing systemic inflammation.
Improved Joint Mobility
By reducing inflammation and promoting tissue repair, regenerative approaches supports restore range of motion and flexibility in affected joints.
Cartilage Regeneration
Mesenchymal stem cells stimulate the production of new cartilage matrix, helping to repair damaged joint surfaces and slow further deterioration.
Pain Reduction
The anti-inflammatory properties of MSCs provide significant pain relief by addressing the underlying causes of joint inflammation rather than just masking symptoms.
Minimally Invasive
The Regenerative Approach is a non-surgical treatment option that avoids the risks, recovery time, and complications associated with joint replacement surgery.
Long-Lasting Results
Unlike temporary symptom relief from medications, regenerative medicine approach aims to create lasting improvements by promoting genuine tissue repair and regeneration.
How Stem Cells Work for Arthritis
MSC therapy for arthritis targets the joint inflammation, cartilage degradation, and immune dysfunction that drive both rheumatoid arthritis and osteoarthritis. Clinical studies suggest that MSCs can regenerate damaged cartilage, modulate autoimmune joint attacks, and reduce chronic synovial inflammation to restore joint function.
MSCs differentiate into chondrocytes and stimulate native cartilage cell proliferation by secreting growth factors including TGF-B, bone morphogenetic proteins (BMPs), and insulin-like growth factor (IGF-1). Clinical research indicates this promotes the formation of new cartilage matrix, helping to repair damaged articular surfaces and restore joint cushioning.
In rheumatoid arthritis, MSCs modulate the overactive immune system by suppressing autoreactive T-cells and reducing the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 that drive synovial inflammation and joint destruction. This immunomodulatory action addresses the autoimmune root cause of RA.
MSCs release matrix metalloproteinase inhibitors (TIMPs) and anti-fibrotic factors that help prevent further cartilage breakdown and protect the joint from ongoing degenerative damage. This protective effect is particularly important in osteoarthritis, where progressive cartilage loss leads to painful bone-on-bone contact.
MSCs secrete anti-inflammatory mediators that reduce chronic synovial inflammation, decrease joint swelling and effusion, and promote the resolution of the inflammatory environment within the joint capsule. This creates conditions favorable for tissue healing and long-term joint health improvement.
Who Is a Good Candidate?
Candidacy for arthritis the regenerative approach is determined through comprehensive rheumatological evaluation, including imaging studies, inflammatory markers, autoantibody panels, and assessment of joint damage severity. Our specialists evaluate each patient to develop a targeted treatment approach.
Ideal Candidates
- Patients with rheumatoid arthritis who have not achieved adequate remission with conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents
- Individuals with moderate osteoarthritis (Kellgren-Lawrence grade II-III) who experience persistent joint pain and reduced mobility despite physical therapy and pain management
- Patients seeking an alternative to joint replacement surgery who want to explore regenerative options to preserve their natural joint function
- Individuals with multiple joint involvement who would benefit from the systemic anti-inflammatory and immunomodulatory effects of intravenous MSC administration
- Patients with early-stage arthritis who want proactive treatment to slow disease progression and prevent further cartilage deterioration
May Not Be Suitable
- Patients with end-stage joint destruction (Kellgren-Lawrence grade IV) with complete cartilage loss and severe bone-on-bone contact, where joint replacement may be the more appropriate intervention
- Individuals with active joint infections (septic arthritis) or systemic infections that must be resolved before regenerative treatment can be considered
- Patients with active malignancy or uncontrolled metabolic conditions that could compromise treatment safety and efficacy
- Individuals with severe joint instability or ligament damage requiring surgical stabilization before regenerative treatment would be beneficial
What Results Can You Expect?
Improvement timelines for arthritis regenerative medicine approach depend on the type and severity of arthritis, number of joints affected, and individual healing response. The following represents a general guide based on clinical data and patient outcomes.
Initial Recovery
the approach is well-tolerated with minimal recovery time. Some patients may experience mild temporary joint soreness at injection sites. Anti-inflammatory effects begin as MSCs start releasing therapeutic factors.
Early Improvements
Many patients begin to notice reductions in joint pain, morning stiffness, and swelling. Improved range of motion during daily activities is commonly reported during this early phase of response.
Progressive Results
More significant improvements in joint function, reduced inflammatory markers, and decreased pain medication requirements are typically observed. Cartilage regeneration processes are actively underway during this period.
Optimal Results
Peak therapeutic benefits are generally achieved, with patients experiencing substantially improved joint mobility, reduced pain, and measurable improvements in inflammatory and autoimmune markers for RA patients.
Long-Term Benefits
Sustained improvements in joint function and pain reduction continue. Follow-up imaging may reveal cartilage thickness improvements. Some patients benefit from additional treatments to further enhance regenerative outcomes.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Your Arthritis Treatment Journey
Our comprehensive five-step protocol ensures safe, effective, and personalized regenerative medicine application for your arthritis condition.
Medical Assessment
Comprehensive evaluation of your arthritis type, severity, joint involvement, and overall health to determine treatment suitability.
Diagnostic Review
Analysis of imaging studies, blood work, and inflammatory markers to create a detailed picture of your joint condition.
Care Planning
Development of a personalized MSC therapy protocol tailored to your specific arthritis type and treatment goals.
Stem Cell Administration
Precise delivery of GMP-certified umbilical cord-derived mesenchymal stem cells through targeted intravenous and intra-articular injections.
Follow-Up & Monitoring
Regular post-treatment assessments to track inflammation levels, joint function improvement, and overall response.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"My orthopaedic surgeon in Munich said I'd need a new knee within a year. After regenerative medicine in Istanbul, that was two years ago and I still don't need it."
"I spent years managing pain instead of living. The treatment in Turkey gave me my active life back — something I didn't think was possible at my age."
Frequently Asked Questions About Arthritis Treatment
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Spinal Cord Injury Rehabilitation with Stem Cells
Learn about advanced regenerative medicine applications that are supporting patients with spinal cord injuries in regaining sensation and mobility through physician-directed protocols.
Read ArticleUnderstanding Regenerative Medicine: A Complete Guide
A comprehensive overview of stem cell therapy, including types of stem cells, care processes, safety considerations, and what patients can expect during their wellness journey.
Read ArticleComplete Guide to Stem Cells and Their Types
Explore the different types of stem cells - adult, fetal, embryonic, and cord blood - their unique characteristics, therapeutic applications, and how they're advancing regenerative medicine.
Read ArticleHow Much Does This Cost Worldwide?
Compare this regenerative medicine costs at StemCell Longevita versus clinics in other countries.
| Country | Typical Cost |
|---|---|
| United States | $15,000 – $25,000 |
| United Kingdom | £12,000 – £20,000 |
| Germany | €15,000 – €25,000 |
| South Korea | $12,000 – $20,000 |
| StemCell Longevita (Turkey) | From £5,900 |
Prices based on market research of comparable stem cell clinics offering umbilical cord-derived MSC treatments (2025-2026). Actual prices vary by clinic, cell count, and condition.
Detailed guides for this condition:
Related clinical questions
Where this page sits in the wider picture.